NCT02221999View on ClinicalTrials.gov

Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2029

Conditions
Tubular Breast CancerMucinous Breast CancerInvasive Ductal Breast CancerInflammatory Breast Cancer
Interventions
DRUG

Paclitaxel

DRUG

Cisplatin

DRUG

Gonadotropin-releasing hormone agonist

Goserelin 3.6 mg q28d or Leuprolide 11.25 mg q3m

DRUG

Letrozole

Trial Locations (12)

200032

Zhongshan Hospital, Shanghai

200127

Shanghai Jiaotong University School of Medicine, Renji Hospital, Shanghai

200437

Yueyang hospital of integrated traditional Chinese and Western medine, Shanghai

201103

Armed Police Corps Hospital of Shanghai, Shanghai

215300

The second people's hospital of Kunshan city, Kunshan

316021

Zhoushan hospital, Zhoushan

421001

The First Affiliated Hospital of University of South China, Hengyang

Unknown

Department of Thyroid and Breast Gland Surgery,Shenzhen Longgang Central Hospital, Shenzhen

Department of Thyroid and Breast Surgery, The Affiliated Hospital of Inner Mongolia Medical Collage, Hohhot

Department of Medical Oncology, General Hospital of Ningxia Medical University, Yinchuan

Department of Breast Surgery, Obstetrics and Gynecology Hospital of Fudan University, Shanghai

056001

HanDan Central Hospital, Handan

All Listed Sponsors
lead

RenJi Hospital

OTHER